135 related articles for article (PubMed ID: 7842401)
1. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts.
van der Zee AG; de Cuyper EM; Limburg PC; de Bruijn HW; Hollema H; Bijzet J; Krans M; de Vries EG
Cancer; 1995 Feb; 75(4):1004-9. PubMed ID: 7842401
[TBL] [Abstract][Full Text] [Related]
2. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer.
Gastl G; Plante M; Finstad CL; Wong GY; Federici MG; Bander NH; Rubin SC
Br J Haematol; 1993 Mar; 83(3):433-41. PubMed ID: 8485049
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer.
Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kulesza-Bronczyk B; Kinalski M; Terlikowski SJ
Eur Cytokine Netw; 2013; 24(3):106-13. PubMed ID: 24197277
[TBL] [Abstract][Full Text] [Related]
4. Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours.
Daraï E; Detchev R; Hugol D; Quang NT
Hum Reprod; 2003 Aug; 18(8):1681-5. PubMed ID: 12871882
[TBL] [Abstract][Full Text] [Related]
5. [Medium-weight molecules in the blood serum of patients with hyperplastic processes in the endometrium and benign and malignant ovarian tumors].
Nikolaenkova VA; Alenina TV; Sterliagova LI
Akush Ginekol (Mosk); 1991 Oct; (10):56-8. PubMed ID: 1789328
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
[TBL] [Abstract][Full Text] [Related]
7. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer.
Moradi MM; Carson LF; Weinberg B; Haney AF; Twiggs LB; Ramakrishnan S
Cancer; 1993 Oct; 72(8):2433-40. PubMed ID: 8402460
[TBL] [Abstract][Full Text] [Related]
8. Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer.
Sanguinete MMM; Oliveira PH; Martins-Filho A; Micheli DC; Tavares-Murta BM; Murta EFC; Nomelini RS
Immunol Invest; 2017 Oct; 46(7):677-688. PubMed ID: 28872976
[TBL] [Abstract][Full Text] [Related]
9. Concomitant measurements of interleukin-6 (IL-6) in serum and peritoneal fluid of patients with benign and malignant ovarian tumors.
Schröder W; Ruppert C; Bender HG
Eur J Obstet Gynecol Reprod Biol; 1994 Jul; 56(1):43-6. PubMed ID: 7982516
[TBL] [Abstract][Full Text] [Related]
10. Cytokine profiles in cyst fluids from ovarian tumors reflect immunosuppressive state of the tumor.
Yigit R; Massuger LF; Zusterzeel PL; Pots J; Figdor CG; Torensma R
Int J Gynecol Cancer; 2011 Oct; 21(7):1241-7. PubMed ID: 21946293
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer.
Plante M; Rubin SC; Wong GY; Federici MG; Finstad CL; Gastl GA
Cancer; 1994 Apr; 73(7):1882-8. PubMed ID: 8137215
[TBL] [Abstract][Full Text] [Related]
12. The chemotactic cytokine interleukin-8--a cyst fluid marker for malignant epithelial ovarian cancer?
Ivarsson K; Runesson E; Sundfeldt K; Haeger M; Hedin L; Janson PO; Brännström M
Gynecol Oncol; 1998 Dec; 71(3):420-3. PubMed ID: 9887242
[TBL] [Abstract][Full Text] [Related]
13. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
Nowak M; Glowacka E; Szpakowski M; Szyllo K; Malinowski A; Kulig A; Tchorzewski H; Wilczynski J
Neuro Endocrinol Lett; 2010; 31(3):375-83. PubMed ID: 20588232
[TBL] [Abstract][Full Text] [Related]
14. Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors.
Hayashi M; Shibazaki M; Sohma R; Inaba N
Am J Med Sci; 2006 Oct; 332(4):181-5. PubMed ID: 17031243
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination.
Chechlinska M; Kaminska J; Markowska J; Kramar A; Steffen J
Int J Biol Markers; 2007; 22(3):172-80. PubMed ID: 17922459
[TBL] [Abstract][Full Text] [Related]
16. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor in ovarian cyst fluid.
Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; Boonstra H; Sweep CG
Cancer; 2001 Jan; 91(2):371-7. PubMed ID: 11180084
[TBL] [Abstract][Full Text] [Related]
18. Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors.
Arts HJ; de Jong S; Hollema H; Ten Hoor KA; de Vries EG; van der Zee AG
Int J Oncol; 2005 Feb; 26(2):379-84. PubMed ID: 15645122
[TBL] [Abstract][Full Text] [Related]
19. Serum and cystic fluid levels of soluble interleukin-2 receptor-alpha in patients with epithelial ovarian tumors are correlated.
de Bruijn HW; ten Hoor KA; van der Zee AG
Tumour Biol; 1998; 19(3):160-6. PubMed ID: 9591042
[TBL] [Abstract][Full Text] [Related]
20. Measurement of glycodelin A in fluids of benign ovarian cysts, borderline tumours and malignant ovarian cancer.
Bischof A; Briese V; Richter DU; Bergemann C; Friese K; Jeschke U
Anticancer Res; 2005; 25(3A):1639-44. PubMed ID: 16033074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
